JP2003530307A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003530307A5 JP2003530307A5 JP2001508378A JP2001508378A JP2003530307A5 JP 2003530307 A5 JP2003530307 A5 JP 2003530307A5 JP 2001508378 A JP2001508378 A JP 2001508378A JP 2001508378 A JP2001508378 A JP 2001508378A JP 2003530307 A5 JP2003530307 A5 JP 2003530307A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- adenovirus
- gene
- vaccine
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013598 vector Substances 0.000 description 32
- 241000701161 unidentified adenovirus Species 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- 101710177291 Gag polyprotein Proteins 0.000 description 8
- 101710125418 Major capsid protein Proteins 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 229940021704 adenovirus vaccine Drugs 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 101150029662 E1 gene Proteins 0.000 description 5
- 230000002950 deficient Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 3
- 101150005585 E3 gene Proteins 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 108010057360 Adenovirus E1 Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14263199P | 1999-07-06 | 1999-07-06 | |
| US60/142,631 | 1999-07-06 | ||
| US14898199P | 1999-08-13 | 1999-08-13 | |
| US60/148,981 | 1999-08-13 | ||
| PCT/US2000/018332 WO2001002607A1 (en) | 1999-07-06 | 2000-07-03 | Adenovirus carrying gag gene hiv vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003530307A JP2003530307A (ja) | 2003-10-14 |
| JP2003530307A5 true JP2003530307A5 (enExample) | 2006-12-07 |
Family
ID=26840267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001508378A Withdrawn JP2003530307A (ja) | 1999-07-06 | 2000-07-03 | ｇａｇ遺伝子保有アデノウイルスＨＩＶワクチン |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US6787351B2 (enExample) |
| EP (1) | EP1200622A4 (enExample) |
| JP (1) | JP2003530307A (enExample) |
| CA (1) | CA2378539A1 (enExample) |
| WO (1) | WO2001002607A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020088014A1 (en) * | 1996-05-31 | 2002-07-04 | Xiangming Fang | Minimal adenovirus mediated recombinant vaccine |
| GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| CA2358385C (en) | 1998-12-31 | 2013-08-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| WO2000039302A2 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| AU2002211948B2 (en) | 2000-03-02 | 2007-09-13 | Emory University | DNA expression vectors and methods of use |
| US8623379B2 (en) | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
| US20020155127A1 (en) * | 2000-06-02 | 2002-10-24 | Danher Wang | Genetic vaccine against human immunodeficiency virus |
| US7754201B2 (en) * | 2000-06-02 | 2010-07-13 | GenPhar, Inc | Method of vaccination through serotype rotation |
| JP2004504035A (ja) * | 2000-07-14 | 2004-02-12 | ユニバーシティ オブ サスカチュワン | イントロンを含むアデノウイルスベクター |
| US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
| AU2002211710A1 (en) * | 2000-10-13 | 2002-04-22 | Chiron Corporation | Cytomegalovirus intron a fragments |
| DE60234018D1 (de) | 2001-03-08 | 2009-11-26 | Univ Emory | Mva-exprimierende modifizierte hiv-envelope-, gag-, und pol-gene |
| JP5033303B2 (ja) | 2001-07-05 | 2012-09-26 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用 |
| GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| EP1436397B1 (en) | 2001-10-11 | 2010-05-12 | Merck Sharp & Dohme Corp. | Hepatitis c virus vaccine |
| CA2852277C (en) | 2001-11-21 | 2018-02-20 | Guangping Gao | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| GB2396814B (en) | 2001-11-30 | 2006-07-19 | Isis Innovation | Fowlpox vector |
| JP2005519959A (ja) * | 2002-03-13 | 2005-07-07 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖに対する強化された免疫応答を誘導する方法 |
| EP1492891B1 (en) | 2002-03-29 | 2008-02-20 | Merck & Co., Inc. | Methods of virus production |
| EP1783212B1 (en) | 2002-05-14 | 2011-01-05 | Merck Sharp & Dohme Corp. | Methods of adenovirus purification |
| US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
| AU2003288273A1 (en) | 2002-10-23 | 2004-05-13 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| AU2003298361B2 (en) | 2002-12-17 | 2009-05-14 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
| EP1663114A2 (en) * | 2003-09-18 | 2006-06-07 | Merck & Co., Inc. | Therapeutic immunization of hiv-infected individuals |
| WO2005110492A2 (en) * | 2004-04-12 | 2005-11-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of using adenoviral vectors to induce an immune response |
| AU2005293568B2 (en) | 2004-10-13 | 2010-10-28 | Beth Israel Deaconess Medical Center Inc. | Improved adenoviral vectors and uses thereof |
| WO2007050095A2 (en) | 2004-11-19 | 2007-05-03 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
| US20090181424A1 (en) * | 2005-04-22 | 2009-07-16 | Fernando Albericio | Mammalian Expression Vector Comprising the MCMV Promoter and First Intron of HCMV Major Immediate Early Gene |
| JP2009520790A (ja) * | 2005-12-21 | 2009-05-28 | グラクソ グループ リミテッド | 免疫応答を惹起する方法 |
| JP5409354B2 (ja) * | 2006-05-25 | 2014-02-05 | インスティチュート フォー アドバンスド スタディ | 配列モチーフを同定するための方法、およびその応用 |
| CA2657626C (en) | 2006-07-13 | 2020-02-25 | Institute For Advanced Study | Viral inhibitory nucleotide sequences and vaccines |
| US8926993B2 (en) | 2006-07-17 | 2015-01-06 | Aduro Biotech | Methods and compositions using Listeria for enhancing immunogenicity by prime boost |
| GB0706914D0 (en) | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel adenovirus vectors |
| WO2009026183A1 (en) * | 2007-08-17 | 2009-02-26 | The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Use of chimeric hiv/siv gag proteins to optimize vaccine-induced t cell responses against hiv gag |
| BRPI0914224A2 (pt) | 2008-06-19 | 2019-09-24 | Variation Biotechnologies Inc | composições e métodos para tratar a gripe |
| EP2213299B1 (fr) | 2009-01-29 | 2015-09-09 | Michel Vandevelde | Composition vaccinale à base de virus exhibant une protéine à motif(s) en doigt de zinc, son procédé de préparation et son utilisation |
| WO2011005772A1 (en) | 2009-07-06 | 2011-01-13 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| AU2010270722B2 (en) | 2009-07-06 | 2015-06-04 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| BRPI0914507A2 (pt) * | 2009-12-23 | 2012-04-10 | Fundacao Oswaldo Cruz | vacina para lentivìrus baseada em vìrus recombinante vacinal da febre amarela |
| CA2840079C (en) | 2010-07-06 | 2018-07-03 | Variation Biotechnologies Inc. | Compositions and methods for treating influenza |
| MX359103B (es) | 2011-01-13 | 2018-09-14 | Variation Biotechnologies Inc | Composiciones y sus usos en el tratamiento de infecciones virales. |
| US10183069B2 (en) * | 2011-03-21 | 2019-01-22 | Altimmune Inc. | Rapid and prolonged immunologic-therapeutic |
| SG194079A1 (en) | 2011-04-06 | 2013-11-29 | Biovaxim Ltd | Pharmaceutical compositions for preventing and/or treating an hiv disease in humans |
| US20140356399A1 (en) | 2012-01-12 | 2014-12-04 | Variation Biotechnologies, Inc. | Compositions and methods for treating viral infections |
| CA2894467A1 (en) | 2012-01-27 | 2013-08-01 | Variation Biotechnologies Inc. | Methods for preparing thermostable compositions comprising a lipid component and thermolabile therapeutic agents |
| ES2582504T3 (es) | 2012-03-12 | 2016-09-13 | Crucell Holland B.V. | Lotes de adenovirus recombinantes con extremos alterados |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| KR101466874B1 (ko) * | 2012-05-11 | 2014-12-03 | 가톨릭대학교 산학협력단 | 자가면역 질환의 예방과 치료를 위한 ｉｌ-６ 수용체에 대한 항체를 발현하는 미니서클 |
| KR101466875B1 (ko) * | 2012-05-11 | 2014-12-03 | 가톨릭대학교 산학협력단 | 항종양괴사인자 수용체 2를 발현하도록 설계된 미니서클 벡터를 이용한 자가면역질환 치료 |
| EP4631509A2 (en) | 2012-11-16 | 2025-10-15 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and use thereof |
| SI3271729T1 (sl) | 2015-03-18 | 2021-04-30 | Janssen Vaccines & Prevention B.V. | Testi za rekombinantne ekspresijske sisteme |
| US10570417B2 (en) | 2015-04-14 | 2020-02-25 | Janssen Vaccines & Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
| CN109312362B (zh) | 2016-06-20 | 2022-06-28 | 扬森疫苗与预防公司 | 有效和平衡的双向启动子 |
| EP3704138A1 (en) | 2017-10-31 | 2020-09-09 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| MX421606B (es) | 2017-10-31 | 2025-03-14 | Janssen Vaccines & Prevention Bv | Vectores adenovirales y usos de estos |
| KR20200083510A (ko) | 2017-10-31 | 2020-07-08 | 얀센 백신스 앤드 프리벤션 비.브이. | 아데노바이러스 및 이의 용도 |
| EA202091074A1 (ru) | 2017-10-31 | 2020-07-22 | Янссен Вэксинс Энд Превеншн Б.В. | Аденовирус и его применения |
| WO2019118480A1 (en) | 2017-12-11 | 2019-06-20 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and uses thereof |
| WO2020243485A1 (en) | 2019-05-29 | 2020-12-03 | Massachusetts Institute Of Technology | Hiv-1 specific immunogen compositions and methods of use |
| BR112022005268A2 (pt) | 2019-10-03 | 2022-08-16 | Janssen Vaccines & Prevention Bv | Vetores adenovirais e usos dos mesmos |
| US11571672B2 (en) | 2019-11-25 | 2023-02-07 | Saudi Arabian Oil Company | Method of providing catalysts for a fluidized bed reactor |
| CN111949888B (zh) * | 2020-09-02 | 2023-10-10 | 度小满科技(北京)有限公司 | 一种数据推荐方法及装置 |
| WO2025242657A1 (en) | 2024-05-21 | 2025-11-27 | Shape Biopharmaceuticals Ag | Lipopeptide building blocks and aggregates |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643579A (en) | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
| US5716826A (en) * | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| CA2003383A1 (en) * | 1988-11-23 | 1990-05-23 | Sushil G. Devare | Synthetic dna derived recombinant hiv antigens |
| DE69333057T2 (de) | 1992-08-07 | 2004-07-08 | Wyeth | Rekombinente Adenoviren-Impfstoffe |
| FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| ES2196018T3 (es) | 1993-08-11 | 2003-12-16 | Wyeth Corp | Vacunas de adenovirus recombinantes. |
| US6204052B1 (en) | 1994-08-16 | 2001-03-20 | Introgene B.V. | Adenoviral vectors with reduced TNF response and partial E3 region deletion |
| PT800579E (pt) | 1994-12-30 | 2002-12-31 | Chiron Corp | Veiculos de distribuicao de genes de combinacao |
| WO1996039178A1 (en) | 1995-06-05 | 1996-12-12 | The Wistar Institute Of Anatomy And Biology | A replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| US6019978A (en) | 1995-06-05 | 2000-02-01 | The Wistar Institute Of Anatomy And Biology | Replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| DE69638058D1 (de) | 1995-06-15 | 2009-11-26 | Crucell Holland Bv | Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie |
| US5672508A (en) * | 1996-01-23 | 1997-09-30 | Mitotix, Inc. | Inhibitors of cell-cycle progression, and uses related thereto |
| EP0904380B1 (en) | 1996-02-22 | 2005-11-09 | Merck & Co., Inc. | Synthetic hiv genes |
| AU2678797A (en) | 1996-04-22 | 1997-11-12 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Heterologous boosting immunizations |
| WO1997048370A2 (en) | 1996-06-21 | 1997-12-24 | Merck & Co., Inc. | Vaccines comprising synthetic genes |
| IL131131A0 (en) | 1997-02-07 | 2001-01-28 | Merck & Co Inc | Synthetic hiv gag genes |
| GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| EP1199089A1 (en) | 1999-06-30 | 2002-04-24 | Javier Garrigues Mateo | Off side detection system |
| GB9922361D0 (en) | 1999-09-21 | 1999-11-24 | Isis Innovation | Generating an immune response to an antigen |
| CA2393861A1 (en) | 1999-12-17 | 2001-06-21 | Merck & Co., Inc. | Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef |
| AU779951B2 (en) | 1999-12-22 | 2005-02-24 | Merck & Co., Inc. | Polynucleotide vaccines expressing codon optimized HIV-1 pol and modified HIV-1 pol |
-
2000
- 2000-07-03 CA CA002378539A patent/CA2378539A1/en not_active Abandoned
- 2000-07-03 WO PCT/US2000/018332 patent/WO2001002607A1/en not_active Ceased
- 2000-07-03 JP JP2001508378A patent/JP2003530307A/ja not_active Withdrawn
- 2000-07-03 EP EP00945133A patent/EP1200622A4/en not_active Withdrawn
-
2001
- 2001-03-27 US US09/818,443 patent/US6787351B2/en not_active Expired - Fee Related
-
2003
- 2003-06-13 US US10/461,030 patent/US20030228329A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003530307A5 (enExample) | ||
| JP7053728B2 (ja) | 組換えアデノウイルスおよびその使用 | |
| US11104916B2 (en) | Compositions and methods for alphavirus vaccination | |
| US12285481B2 (en) | Methods for the treatment of COVID-19 comprising administering replication-defective adenoviruses encoding the SARS-CoV-2 spike glycoprotein and modified nucleocapsid protein | |
| US20220062409A1 (en) | Heterologous prime boost vaccine compositions and methods | |
| TWI828168B (zh) | 用作b型肝炎病毒(hbv)疫苗之自我複製rna分子及其用途 | |
| JP2008110963A (ja) | 調節剤の粘膜投与による感染している哺乳類における免疫応答の調節方法 | |
| JP2002533124A5 (enExample) | ||
| EP1825863A1 (en) | Recombinant porcine adenovirus vector | |
| JP2005505286A5 (enExample) | ||
| JPH09511143A (ja) | アルファーウイルスｃＤＮＡベクター | |
| KR20230050328A (ko) | Hbv에 대한 rna 레플리콘 백신 | |
| JP2004501650A5 (enExample) | ||
| CN111363726A (zh) | 表达干扰素的溶瘤病毒及其应用 | |
| JP2004501646A5 (enExample) | ||
| KR20200100745A (ko) | B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물 | |
| CN100471957C (zh) | 用于免疫治疗的腺病毒载体 | |
| Kon et al. | Naked plasmid‐mediated gene transfer to skeletal muscle ameliorates diabetes mellitus | |
| CA2461579A1 (en) | Porcine adenovirus e1 region | |
| CN101155826B (zh) | 作为疫苗的复制缺陷型rna病毒 | |
| Chengalvala et al. | Adenovirus vectors for gene expression | |
| KR100686356B1 (ko) | 중공 나노입자를 형성하는 단백질에 질환 치료용 세포도입 물질을 융합시킨 약제 | |
| JP2008521384A (ja) | コロナウィルス様粒子をコードする発現ベクター | |
| CA2501633A1 (fr) | Vecteurs adenoviraux recombinants et leurs applications | |
| Pergolizzi et al. | Protective immunity against α-cobratoxin following a single administration of a genetic vaccine encoding a non-toxic cobratoxin variant |